Compare Nomura Holdings Inc (NMR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Sana Biotechnology Inc — how do they compare? Nomura Holdings Inc trades at $9.49 (market cap $27.55B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Nomura Holdings Inc is far larger — about 32.9× Sana Biotechnology Inc's market cap, and Nomura Holdings Inc pays a 3.4% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nomura Holdings Inc for 55 Days and Sana Biotechnology Inc for 23 Days on average.
| NMR | SANA | |
|---|---|---|
Market Cap | $27.55B | $836.71M |
Volume | 782,470 | 4,507,444 |
Sector | Financials | Health |
52-Week High | $10.86 | $5.92 |
52-Week Low | $6.73 | $2.68 |
Typical Hold Time | 55 Days | 23 Days |
Enterprise Value | $38.54T | $749.96M |
Dividend Yield | 3.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.53, down 2.56% today amid bearish technical signals. The stock shows mixed fundamentals with strong revenue growth to $1.66T in 2025 and net income margin of 20.4%, but recent earnings misses and negative operating cash flow raise concerns. Valuation appears reasonable with P/E of 11.29 and P/B of 1.15. Analyst consensus leans cautious with 67% hold ratings despite recent Zacks strong buy recommendations.
NMR presents a value opportunity with attractive valuation multiples, though execution risks persist. The bearish technical trend and inconsistent earnings performance warrant caution. Upside potential exists if the company can sustain revenue growth and improve cash flow generation, but investors should monitor debt levels increasing to 26.25% of assets.
SANA Biotechnology trades at $2.72, down 1.09% with a bearish technical signal despite bullish oscillators. The company shows significant financial challenges with negative revenue, a net loss of $244.17 million in 2025, and negative cash flow. However, analyst sentiment remains positive with 82% buy ratings and recent conference presentations highlighting ongoing research in engineered cell therapies.
The outlook is highly speculative given the pre-revenue stage and substantial losses. Investment opportunity lies in the potential of SANA's biotechnology platform, but risks include cash burn, clinical trial outcomes, and competitive pressures. Wall Street maintains cautious optimism despite fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
